Chronic Disease Management — MCQs
On this page
A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout attends for review. His medications include: metformin 500mg BD, gliclazide 160mg BD, aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 10mg OD, ramipril 10mg OD, furosemide 40mg OD, and allopurinol 100mg OD. Recent HbA1c is 64 mmol/mol. He reports two episodes of feeling shaky and sweaty in the past month, relieved by eating. What is the most appropriate next step in his medication management?
A 74-year-old woman with heart failure (NYHA class II), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a presents for medication review. She takes bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and atorvastatin. Her recent blood tests show: eGFR 48 ml/min/1.73m², potassium 5.2 mmol/L, HbA1c 58 mmol/mol. She reports good adherence and no symptoms of heart failure decompensation. What concept best explains why further intensification of her heart failure treatment should be approached cautiously?
During a medication review of a 72-year-old man with type 2 diabetes, COPD, and hypertension, you identify that he is taking metformin 1g BD, gliclazide 80mg BD, bisoprolol 5mg OD, ramipril 10mg OD, salbutamol inhaler PRN, and tiotropium inhaler OD. His recent HbA1c is 52 mmol/mol, BP 128/78 mmHg, and he reports no hypoglycaemic episodes. What aspect of his medication regimen best demonstrates the principle of treatment burden in multimorbidity?
A 67-year-old woman with asthma, hypertension, osteoarthritis, hypothyroidism, and depression presents for review. She takes salbutamol, beclometasone inhaler, amlodipine, ramipril, levothyroxine, paracetamol, ibuprofen, and sertraline. She reports good control of all conditions but mentions occasional indigestion. What is the most appropriate understanding of her polypharmacy status?
A 78-year-old man with multiple comorbidities attends for review. He takes 13 different medications daily. According to current UK guidance on medicines optimisation in patients with polypharmacy, what is the recommended minimum frequency for structured medication reviews in this patient?
A practice pharmacist reviews prescribing data and identifies that 18% of patients with heart failure and reduced ejection fraction are not prescribed an ACE inhibitor or angiotensin receptor blocker (ARB), and 35% are not on a beta-blocker. Many have documented 'patient declined' or 'not tolerated' in their records from several years ago. From a multimorbidity management perspective, which single interpretation of this data is most appropriate?
During a comprehensive medication review for a 75-year-old woman with COPD, hypertension, atrial fibrillation, and depression, you identify she is taking 12 regular medications. She reports feeling overwhelmed by her medication regimen and sometimes missing doses. According to principles of medicines optimization, which single approach would best support her adherence?
A 77-year-old man with type 2 diabetes, heart failure (LVEF 30%), and recurrent falls takes metformin, gliclazide, insulin glargine, bisoprolol, ramipril, furosemide, and atorvastatin. His HbA1c is 42 mmol/mol, and he has had three episodes of documented hypoglycaemia (glucose 2.8-3.2 mmol/L) in the past month, two occurring at night. Which single medication adjustment would most appropriately address his hypoglycaemia risk while maintaining adequate glycaemic control?
You are evaluating the implementation of a structured medication review service for patients with polypharmacy in your practice. Initial data shows that 45% of patients aged over 75 on 10+ medications have had a structured review in the past 12 months. The QOF target is at least annual review. Which single factor would most significantly improve the effectiveness of medication reviews in reducing adverse outcomes?
A 68-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and stage 3a CKD takes methotrexate, folic acid, hydroxychloroquine, alendronic acid, calcium/vitamin D, amlodipine, and lansoprazole. She has been on lansoprazole for 4 years, originally started for dyspepsia. She is concerned about long-term PPI use after reading about risks. Her rheumatoid arthritis is well controlled. What is the single most appropriate management of her PPI therapy?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 121: A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout attends for review. His medications include: metformin 500mg BD, gliclazide 160mg BD, aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 10mg OD, ramipril 10mg OD, furosemide 40mg OD, and allopurinol 100mg OD. Recent HbA1c is 64 mmol/mol. He reports two episodes of feeling shaky and sweaty in the past month, relieved by eating. What is the most appropriate next step in his medication management?
- A. Add empagliflozin 10mg OD for additional cardiovascular and renal protection
- B. Stop metformin due to CKD stage 3b and replace with a DPP-4 inhibitor
- C. Reduce or stop gliclazide and consider replacing with a GLP-1 receptor agonist or SGLT-2 inhibitor (Correct Answer)
- D. Increase allopurinol to 300mg OD to improve uric acid control and reduce cardiovascular risk
- E. Add spironolactone 25mg OD to optimise heart failure management
Explanation: ***Reduce or stop gliclazide and consider replacing with a GLP-1 receptor agonist or SGLT-2 inhibitor*** - The patient is experiencing symptomatic **hypoglycaemia** (shaky, sweaty, relieved by food), and **Gliclazide** is the most likely cause, as it is a **sulfonylurea** that carries a high risk of low blood sugar, especially in patients with **CKD** due to impaired drug clearance. - Replacing it with an **SGLT-2 inhibitor** or **GLP-1 receptor agonist** addresses the hypoglycaemia risk and provides superior **cardiovascular and renal protection** for his heart failure (LVEF 38%) and Stage 3b CKD without inducing hypoglycaemia. *Add empagliflozin 10mg OD for additional cardiovascular and renal protection* - While an **SGLT-2 inhibitor** like empagliflozin is strongly indicated for his heart failure and CKD, simply adding it to his current regimen does not address the immediate danger of **Gliclazide-induced hypoglycaemia**. - The clinical priority in a patient already experiencing symptomatic hypos is to **deprescribe** or reduce the offending agent (Gliclazide) before adding new glucose-lowering drugs, especially if the HbA1c is not excessively high. *Stop metformin due to CKD stage 3b and replace with a DPP-4 inhibitor* - **Metformin** only requires a dose reduction (max 1g/day) at an **eGFR of 30-45 ml/min/1.73m²** and does not need to be stopped entirely until the eGFR falls below **30 ml/min/1.73m²**. The patient's current eGFR is 38. - While a **DPP-4 inhibitor** is weight-neutral and safe in CKD, it does not offer the same robust **cardioprotective benefits** (specifically for HF) as SGLT-2 inhibitors or GLP-1 receptor agonists, nor does stopping metformin address the hypoglycaemia. *Increase allopurinol to 300mg OD to improve uric acid control and reduce cardiovascular risk* - Increasing **Allopurinol** does not address the patient's acute presentation of **hypoglycaemia**, which is the most pressing clinical safety issue requiring immediate attention. - In patients with **Stage 3b CKD** (eGFR 38), allopurinol doses should be titrated cautiously, and 100mg OD might already be appropriate, or require careful titration, due to the risk of **Allopurinol Hypersensitivity Syndrome** and renal clearance considerations. *Add spironolactone 25mg OD to optimise heart failure management* - Although **Mineralocorticoid Receptor Antagonists (MRAs)** like spironolactone are indicated for **HFrEF** (LVEF 38%), adding one in a patient with stage 3b CKD already on a high-dose ACE inhibitor (**Ramipril 10mg OD**) poses a significant risk of **hyperkalaemia**. - This intervention also ignores the symptomatic **hypoglycaemia**, which is an immediate safety concern that requires prompt medication adjustment to prevent falls or more severe neuroglycopenic events.
Question 122: A 74-year-old woman with heart failure (NYHA class II), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a presents for medication review. She takes bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and atorvastatin. Her recent blood tests show: eGFR 48 ml/min/1.73m², potassium 5.2 mmol/L, HbA1c 58 mmol/mol. She reports good adherence and no symptoms of heart failure decompensation. What concept best explains why further intensification of her heart failure treatment should be approached cautiously?
- A. Therapeutic ceiling - the maximum benefit from ACE inhibitor and beta-blocker has been achieved
- B. Diminishing returns - additional benefit from further treatment is outweighed by potential harm (Correct Answer)
- C. Therapeutic competition - treatments for different conditions are working against each other
- D. Cascading prescribing - adding medications to treat side effects of existing medications
- E. Treatment saturation - the patient is at maximum capacity for medication adherence
Explanation: ***Diminishing returns - additional benefit from further treatment is outweighed by potential harm*** - This patient exhibits **diminishing returns** because she is already on guideline-directed therapy for heart failure, and further intensification poses significant risks like **hyperkalaemia** (potassium already 5.2 mmol/L) or **acute kidney injury** due to her stage 3a **CKD**. - In **multimorbidity**, the incremental benefit of adding a new drug often decreases while the **cumulative risk** of adverse effects and drug interactions increases, making further intensification less favorable. *Therapeutic ceiling - the maximum benefit from ACE inhibitor and beta-blocker has been achieved* - This refers to a pharmacological limit where increasing the dose no longer produces a **therapeutic effect**, rather than a clinical balance of risks and benefits. - The patient is currently asymptomatic at **NYHA class II**, but the reason to stop is not necessarily pharmacological saturation, but clinical safety regarding **potassium** and **renal function**. *Therapeutic competition - treatments for different conditions are working against each other* - This occurs when a drug for one condition, such as an **NSAID**, worsens another condition, such as **Heart Failure**; this is not the primary issue here as her drugs are generally compatible. - While some drugs like **spironolactone** and **ramipril** both affect the kidneys, they are indicated for the same condition rather than treating competing pathologies. *Cascading prescribing - adding medications to treat side effects of existing medications* - This describes a cycle where a **side effect** of one drug is misinterpreted as a new medical condition, leading to another prescription (e.g., prescribing a diuretic for **amlodipine-induced edema**). - It is not applicable here as the patient's current medications address her specific diagnosed comorbidities like **diabetes** and **atrial fibrillation**. *Treatment saturation - the patient is at maximum capacity for medication adherence* - This refers to the **burden of treatment** where a patient can no longer manage the complexity or volume of their regimen, leading to **non-adherence**. - While relevant to elderly patients with polypharmacy, the clinical focus of the question is on the **biochemical risks** (potassium/eGFR) rather than the patient's psychological or logistical ability to take more pills.
Question 123: During a medication review of a 72-year-old man with type 2 diabetes, COPD, and hypertension, you identify that he is taking metformin 1g BD, gliclazide 80mg BD, bisoprolol 5mg OD, ramipril 10mg OD, salbutamol inhaler PRN, and tiotropium inhaler OD. His recent HbA1c is 52 mmol/mol, BP 128/78 mmHg, and he reports no hypoglycaemic episodes. What aspect of his medication regimen best demonstrates the principle of treatment burden in multimorbidity?
- A. The potential for bisoprolol to worsen COPD symptoms and mask hypoglycaemia from gliclazide (Correct Answer)
- B. The use of multiple inhalers requiring different techniques in a patient with diabetes
- C. The need to take gliclazide twice daily with meals while managing multiple other medications
- D. The risk of postural hypotension from the combination of ramipril and bisoprolol
- E. The requirement for regular monitoring of renal function due to metformin and ramipril
Explanation: ***The potential for bisoprolol to worsen COPD symptoms and mask hypoglycaemia from gliclazide*** - This demonstrates **treatment burden** by highlighting how a medication for one condition (hypertension) negatively interferes with the **management and safety** of two other unrelated conditions (COPD and diabetes). - Bisoprolol can cause **bronchoconstriction** in COPD and mask **adrenergic symptoms** of hypoglycaemia (e.g., tremor, palpitations) induced by gliclazide, significantly increasing patient vigilance and risk. *The use of multiple inhalers requiring different techniques in a patient with diabetes* - While this illustrates **practical workload** and potential adherence issues, it primarily focuses on the **mechanical complexity** of polypharmacy, not the intricate therapeutic conflicts between treatments for distinct comorbidities. - It represents a component of treatment burden but not the **cross-condition clinical interactions** that are central to managing multimorbidity. *The need to take gliclazide twice daily with meals while managing multiple other medications* - This points to **regimen complexity** and challenges with medication timing, which is a facet of treatment burden. - However, it represents a relatively straightforward adherence challenge for one drug rather than a **complex therapeutic interaction** or conflict spanning multiple disease systems. *The risk of postural hypotension from the combination of ramipril and bisoprolol* - This is a common **drug-drug interaction** leading to a side effect when combining two antihypertensive medications, affecting the **same disease (hypertension)**. - It adds to monitoring requirements but does not exemplify the **competing priorities** or symptom masking across unrelated conditions typical of high multimorbidity treatment burden. *The requirement for regular monitoring of renal function due to metformin and ramipril* - This represents **healthcare-related workload** (e.g., blood tests, clinic visits) which is part of treatment burden. - However, it is a **routine safety measure** for these medications and does not involve the direct therapeutic conflicts or masking of symptoms between different conditions that demonstrate a higher level of multimorbidity burden.
Question 124: A 67-year-old woman with asthma, hypertension, osteoarthritis, hypothyroidism, and depression presents for review. She takes salbutamol, beclometasone inhaler, amlodipine, ramipril, levothyroxine, paracetamol, ibuprofen, and sertraline. She reports good control of all conditions but mentions occasional indigestion. What is the most appropriate understanding of her polypharmacy status?
- A. This represents problematic polypharmacy requiring immediate deprescribing
- B. This is appropriate polypharmacy but requires gastroprotection with a proton pump inhibitor
- C. This represents appropriate polypharmacy with evidence-based treatments, but the ibuprofen requires review (Correct Answer)
- D. This is minor polypharmacy that does not require structured medication review
- E. This requires urgent referral to a clinical pharmacist for comprehensive review
Explanation: ***This represents appropriate polypharmacy with evidence-based treatments, but the ibuprofen requires review*** - The patient's medications for asthma, hypertension, hypothyroidism, and depression are largely **evidence-based** and she reports good control, indicating appropriate polypharmacy for her chronic conditions. - However, the use of **ibuprofen** (an NSAID) in a 67-year-old taking **ramipril** (an ACE inhibitor) and **sertraline** (an SSRI) poses significant risks of **renal impairment** (the "triple whammy") and **gastrointestinal bleeding/indigestion**, necessitating its review. *This represents problematic polypharmacy requiring immediate deprescribing* - Many of her medications, such as **amlodipine, ramipril, levothyroxine, salbutamol, beclometasone**, and **sertraline**, are essential for managing her well-controlled chronic conditions. - While one medication (ibuprofen) is problematic, labeling the entire regimen as such, and suggesting *immediate deprescribing* of multiple agents, is inappropriate given her stable conditions. *This is appropriate polypharmacy but requires gastroprotection with a proton pump inhibitor* - While gastroprotection might address the indigestion, simply adding a **proton pump inhibitor (PPI)** doesn't resolve the more critical risk of **acute kidney injury** from the combination of **NSAID** and **ACE inhibitor** in an elderly patient. - Prioritizing the addition of another drug over reviewing the potentially harmful drug (ibuprofen) is not the most appropriate initial management strategy. *This is minor polypharmacy that does not require structured medication review* - Taking multiple medications (8 in this case) for several chronic conditions is defined as **polypharmacy**, not minor, especially when a new symptom (indigestion) arises. - The presence of a high-risk medication interaction (**NSAID + ACEi**) and a new symptom definitely warrants a **structured medication review** to optimize therapy and prevent harm. *This requires urgent referral to a clinical pharmacist for comprehensive review* - While a clinical pharmacist's review is valuable, this scenario, though concerning due to the ibuprofen-ramipril interaction, is not an **urgent medical emergency** requiring immediate specialist referral. - A primary care physician or general practitioner should be capable of identifying and addressing this common **drug interaction** and modifying the pain management strategy in a routine consultation.
Question 125: A 78-year-old man with multiple comorbidities attends for review. He takes 13 different medications daily. According to current UK guidance on medicines optimisation in patients with polypharmacy, what is the recommended minimum frequency for structured medication reviews in this patient?
- A. Every 3 months
- B. Every 6 months
- C. Every 12 months (Correct Answer)
- D. Every 18 months
- E. Only when clinically indicated
Explanation: ***Every 12 months*** - According to **NICE guidelines** and standard UK primary care practice, patients on significant **polypharmacy** (often 10+ medications) should undergo a **structured medication review (SMR)** at least **annually**. - This review aims to optimize therapy, reduce **medication-related harm**, and facilitate **deprescribing** where the risks of a drug outweigh the clinical benefits. *Every 3 months* - A 3-month cycle is not the recommended minimum for a routine structured review, as it would likely be unsustainable for **primary care capacity** without specific acute indications. - Such frequent monitoring is usually reserved for specific high-risk drugs like **lithium** or **DMARDs**, rather than a whole-patient medication review. *Every 6 months* - While 6-monthly reviews may be clinically appropriate for individuals with high **clinical complexity** or those moving between care settings, it is not the standard minimum requirement. - Clinicians may choose this frequency for patients with rapidly fluctuating **multimorbidity**, but the baseline recommendation remains yearly. *Every 18 months* - An 18-month interval is considered too long for a patient on 13 medications, as it increases the risk of **adverse drug reactions** going undetected. - Waiting this long exceeds the **national Quality and Outcomes Framework (QOF)** and NICE expectations for proactive medicines optimization. *Only when clinically indicated* - **Structured medication reviews** are intended to be **proactive** and preventative rather than purely reactive to clinical events. - Relying solely on clinical indication ignores the asymptomatic accumulation of **drug-drug interactions** and the slow decline in **renal function** common in elderly patients.
Question 126: A practice pharmacist reviews prescribing data and identifies that 18% of patients with heart failure and reduced ejection fraction are not prescribed an ACE inhibitor or angiotensin receptor blocker (ARB), and 35% are not on a beta-blocker. Many have documented 'patient declined' or 'not tolerated' in their records from several years ago. From a multimorbidity management perspective, which single interpretation of this data is most appropriate?
- A. This represents clear evidence of suboptimal prescribing requiring immediate prescription of these medications
- B. The documentation suggests appropriate shared decision-making and patient choice should be respected
- C. These patients should be identified for clinical review to reassess tolerance and discuss current evidence with patients (Correct Answer)
- D. The practice should implement automatic prescribing protocols for all newly diagnosed heart failure patients
- E. This data suggests patients are appropriately managed as ACE inhibitors and beta-blockers are overemphasized in guidelines
Explanation: ***These patients should be identified for clinical review to reassess tolerance and discuss current evidence with patients***- Documentation of **'patient declined'** or **'not tolerated'** from several years ago does not account for changes in clinical status, newer formulations, or evolving **patient preferences** over time.- Reassessing these patients helps overcome **therapeutic inertia**, ensuring they are offered **evidence-based therapies** like ACE inhibitors and beta-blockers that significantly reduce mortality in **HFrEF**.*This represents clear evidence of suboptimal prescribing requiring immediate prescription of these medications*- Prescribing without a **clinical review** is unsafe as patients may have valid **contraindications** (e.g., severe renal impairment or hyperkalemia) not immediately visible in summary data.- Immediate prescription bypasses the essential process of **informed consent** and individualized assessment required in **multimorbidity management**.*The documentation suggests appropriate shared decision-making and patient choice should be respected*- While prior choices are noted, **shared decision-making** is a continuous process; a decision made years ago may no longer reflect the patient’s **current goals of care**.- Relying solely on historical notes may lead to **under-treatment** of a progressive condition where the benefits of therapy may now outweigh previous concerns.*The practice should implement automatic prescribing protocols for all newly diagnosed heart failure patients*- **Automatic protocols** ignore the complexity of patients with **multimorbidity** who require tailored dosing and monitoring to ensure safety and adherence.- Guidelines emphasize **individualized care**, and a "one size fits all" approach fails to address specific patient **comorbidities** and potential drug interactions.*This data suggests patients are appropriately managed as ACE inhibitors and beta-blockers are overemphasized in guidelines*- These medications are **cornerstone therapies** for heart failure with reduced ejection fraction, with robust evidence supporting their **mortality and morbidity benefits**.- Labelling them as "overemphasized" contradicts current **clinical guidelines** (e.g., NICE, ESC) which prioritize these agents to improve long-term patient outcomes.
Question 127: During a comprehensive medication review for a 75-year-old woman with COPD, hypertension, atrial fibrillation, and depression, you identify she is taking 12 regular medications. She reports feeling overwhelmed by her medication regimen and sometimes missing doses. According to principles of medicines optimization, which single approach would best support her adherence?
- A. Arrange for all medications to be dispensed in a monitored dosage system (blister pack)
- B. Simplify the regimen where possible, explore her concerns, and develop a shared plan with written information (Correct Answer)
- C. Reduce her medication review interval to monthly to ensure better monitoring
- D. Prescribe all medications as once-daily preparations regardless of standard dosing
- E. Arrange for district nurses to supervise all medication administration
Explanation: ***Simplify the regimen where possible, explore her concerns, and develop a shared plan with written information***- This approach aligns with **NICE medicines optimization** guidelines by addressing both **intentional and unintentional non-adherence** through patient-centered communication.- **Simplifying polypharmacy** and providing **written information** reduces the cognitive burden on the patient while fostering **shared decision-making** and engagement.*Arrange for all medications to be dispensed in a monitored dosage system (blister pack)*- **Monitored dosage systems (MDS)** are not a universal solution and there is limited evidence that they improve clinical outcomes or adherence for all patients.- They may reduce a patient's **autonomy** and understanding of their medication, and are intended only for specific needs rather than a first-line intervention for complexity.*Reduce her medication review interval to monthly to ensure better monitoring*- **Monthly reviews** are resource-intensive for the healthcare system and may become an additional burden to the patient without addressing the root cause of feeling overwhelmed.- **Medicines optimization** focuses on the quality of the review and patient empowerment rather than the frequency of appointments.*Prescribe all medications as once-daily preparations regardless of standard dosing*- Changing medications to **once-daily dosing** without regard for pharmacokinetics or clinical evidence can lead to **sub-therapeutic levels** or increased toxicity.- While reducing frequency is helpful, it must be clinically appropriate and evidence-based for each specific drug in the **polypharmacy** regimen.*Arrange for district nurses to supervise all medication administration*- This intervention is overly restrictive for a patient living independently and may lead to a loss of **self-management skills**.- **District nurse** intervention should be reserved for those with physical or cognitive impairments that make self-administration impossible, rather than those who are simply overwhelmed.
Question 128: A 77-year-old man with type 2 diabetes, heart failure (LVEF 30%), and recurrent falls takes metformin, gliclazide, insulin glargine, bisoprolol, ramipril, furosemide, and atorvastatin. His HbA1c is 42 mmol/mol, and he has had three episodes of documented hypoglycaemia (glucose 2.8-3.2 mmol/L) in the past month, two occurring at night. Which single medication adjustment would most appropriately address his hypoglycaemia risk while maintaining adequate glycaemic control?
- A. Stop gliclazide and continue metformin and insulin glargine (Correct Answer)
- B. Stop insulin glargine and increase gliclazide dose to maintain control
- C. Reduce insulin glargine dose by 20% and continue all other diabetes medications
- D. Stop both gliclazide and insulin glargine and start a GLP-1 receptor agonist
- E. Stop metformin as it increases hypoglycaemia risk in combination with sulfonylureas
Explanation: ***Stop gliclazide and continue metformin and insulin glargine*** - The patient's **HbA1c of 42 mmol/mol (6.0%)** is below the target for an elderly, frail individual with comorbidities, indicating **overtreatment** and explaining the recurrent hypoglycaemia. - **Gliclazide**, a sulfonylurea, is a major contributor to **hypoglycaemia**, especially nocturnal events, and should be discontinued first in favour of the safer **metformin** and basal **insulin glargine** combination. *Stop insulin glargine and increase gliclazide dose to maintain control* - Increasing the **gliclazide dose** would significantly exacerbate the risk of **hypoglycaemia**, which is the primary and most dangerous problem for this elderly patient. - Sulfonylureas are associated with less predictable glucose lowering and a higher risk of severe hypoglycaemia compared to basal insulin, making them less suitable for frail patients. *Reduce insulin glargine dose by 20% and continue all other diabetes medications* - While reducing **insulin glargine** might help, continuing **gliclazide** in a patient with recurrent hypoglycaemia and a very low HbA1c still leaves a significant risk of further episodes. - This approach does not fully address the significant risk posed by the **sulfonylurea** in an elderly patient who is already over-treated. *Stop both gliclazide and insulin glargine and start a GLP-1 receptor agonist* - Abruptly stopping both **insulin glargine** and **gliclazide** could lead to uncontrolled hyperglycaemia, and starting a new injectable like a **GLP-1 receptor agonist** may cause gastrointestinal side effects. - While GLP-1 agonists have benefits, the immediate priority in this patient is to safely **deprescribe** the medication most responsible for hypoglycaemia rather than initiating complex new therapies. *Stop metformin as it increases hypoglycaemia risk in combination with sulfonylureas* - **Metformin** has a very low intrinsic risk of **hypoglycaemia** and is generally continued in type 2 diabetes due to its cardiovascular benefits and weight-neutral profile. - Removing metformin while keeping the **sulfonylurea (gliclazide)** would fail to address the primary cause of this patient's recurrent, documented hypoglycaemia.
Question 129: You are evaluating the implementation of a structured medication review service for patients with polypharmacy in your practice. Initial data shows that 45% of patients aged over 75 on 10+ medications have had a structured review in the past 12 months. The QOF target is at least annual review. Which single factor would most significantly improve the effectiveness of medication reviews in reducing adverse outcomes?
- A. Increasing the frequency of medication reviews to every 6 months for all patients
- B. Ensuring medication reviews result in documented agreed actions with follow-up arrangements (Correct Answer)
- C. Training all reception staff to identify patients requiring medication reviews
- D. Implementing computer alerts for all potential drug interactions
- E. Requiring all medication reviews to be conducted by clinical pharmacists
Explanation: ***Ensuring medication reviews result in documented agreed actions with follow-up arrangements*** - A structured review is only effective if it leads to **meaningful clinical changes** that are implemented, monitored, and followed up to ensure safety. - Documentation of **specific actions** (e.g., deprescribing, dose adjustments) and clear **follow-up arrangements** ensures accountability and aligns with **NICE medicines optimization** guidelines. *Increasing the frequency of medication reviews to every 6 months for all patients* - Simply increasing frequency without improving the **quality of the process** does not guarantee better clinical outcomes and may be a poor use of resources. - It risks **process fatigue** and may not prioritize high-risk patients who require more intensive monitoring over stable patients. *Training all reception staff to identify patients requiring medication reviews* - While this improves **identification and scheduling** efficiency, it does not directly impact the **clinical quality** of the review or the management of adverse effects. - Outcomes are determined by the **clinical interventions** made during the review, not the administrative process of flagging patients. *Implementing computer alerts for all potential drug interactions* - Over-reliance on automated alerts often leads to **alert fatigue**, where clinicians ignore significant warnings due to the high volume of clinically irrelevant notifications. - Alerts are a **decision-support tool** but do not replace the comprehensive, patient-centered approach of a structured medication review. *Requiring all medication reviews to be conducted by clinical pharmacists* - While clinical pharmacists have specialized expertise, the **systematic process** and follow-through are more critical for effectiveness than the specific healthcare professional involved. - Effectiveness depends on the **integration of the review** into the patient's care plan and the ability to execute agreed clinical changes across the multidisciplinary team.
Question 130: A 68-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and stage 3a CKD takes methotrexate, folic acid, hydroxychloroquine, alendronic acid, calcium/vitamin D, amlodipine, and lansoprazole. She has been on lansoprazole for 4 years, originally started for dyspepsia. She is concerned about long-term PPI use after reading about risks. Her rheumatoid arthritis is well controlled. What is the single most appropriate management of her PPI therapy?
- A. Continue lansoprazole indefinitely as she needs gastroprotection with methotrexate
- B. Switch to ranitidine as it has fewer long-term risks than PPIs
- C. Attempt gradual PPI withdrawal with on-demand use if dyspepsia recurs (Correct Answer)
- D. Stop lansoprazole immediately and start antacids for symptom relief
- E. Continue lansoprazole as it reduces risk of alendronic acid-related oesophagitis
Explanation: ***Attempt gradual PPI withdrawal with on-demand use if dyspepsia recurs*** - Long-term **proton pump inhibitor (PPI)** use is associated with several risks relevant to this patient, including **osteoporosis** progression (fracture risk), **CKD** progression, and **hypomagnesaemia**. - Since the original indication was **dyspepsia** four years ago and she is not taking high-risk medications like **NSAIDs** or oral steroids, a step-down approach (gradual withdrawal) prevents **rebound acid hypersecretion** and allows for **on-demand therapy** if symptoms return. *Continue lansoprazole indefinitely as she needs gastroprotection with methotrexate* - Low-dose **methotrexate** for rheumatoid arthritis is not a primary indication for routine **gastroprotection** in the absence of **NSAIDs** or significant risk factors. - The patient's **rheumatoid arthritis** is well-controlled, and there is no mention of concurrent gastrotoxic medications that mandate indefinite PPI use. *Switch to ranitidine as it has fewer long-term risks than PPIs* - **Ranitidine**, an H2 receptor antagonist, has been largely withdrawn from many markets due to **nitrosamine contamination** concerns. - While H2 blockers are an alternative for **dyspepsia**, switching does not address the fundamental need for **deprescribing** in a patient with no current clear indication for acid suppression. *Stop lansoprazole immediately and start antacids for symptom relief* - **Immediate cessation** of long-term PPI therapy frequently leads to **rebound acid hypersecretion**, causing a return of symptoms and failed withdrawal. - A **gradual dose reduction** (e.g., lower dose or alternate-day dosing) is clinically preferred over abrupt stopping to improve success rates. *Continue lansoprazole as it reduces risk of alendronic acid-related oesophagitis* - While **alendronic acid** can cause **oesophagitis**, current guidelines do not recommend routine PPI co-prescription just for **bisphosphonate** use. - Paradoxically, chronic PPI use may worsen **osteoporosis** by reducing **calcium absorption**, potentially counteracting the benefits of her **osteoporosis** treatment.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free